Skip to main content

The independent medical news service

Prostate cancer

24-06-2022 | Oncology | News | Article

Focal ultrasound may offer intermediate-risk prostate cancer alternative to radiation, surgery

Magnetic resonance imaging-guided focal ultrasound therapy is a feasible treatment for grade group 2–3 prostate cancer, indicate phase 2b trial findings published in The Lancet Oncology.

22-06-2022 | Oncology | Highlight | Article

Enzalutamide during active surveillance may delay prostate cancer progression

The ENACT trial has demonstrated a significantly reduced risk for progression with the use of enzalutamide in men with low- or intermediate-risk localized prostate cancer undergoing active surveillance.

07-06-2022 | Oncology | News | Article

ENZAMET update confirms benefits of add-on enzalutamide

An updated analysis of the ENZAMET trial confirms earlier findings that adding enzalutamide to testosterone suppression provides statistically and clinically meaningful survival improvements in metastatic hormone-sensitive prostate cancer.

26-05-2022 | Oncology | News | Article

Large study finds no increased risk for prostate cancer death with 5-ARI use

Use of 5α-reductase inhibitors is not associated with an increased risk for prostate cancer mortality, and long-term use may indeed reduce the risk, a Swedish population-based study has found.

19-05-2022 | Oncology | News | Article

ASCO releases guideline on lifestyle changes during cancer treatment

Find out more about the recommendations on exercise, diet, and weight management here

10-05-2022 | Oncology | News | Article

Prostate cancer death linked to increases in BMI, waist size

A meta-analysis has identified a significantly elevated risk for prostate cancer-specific mortality with increases in BMI, waist circumference, and waist-to-hip ratio.

29-04-2022 | Oncology | News | Article

Pharmacovigilance data show prostate cancer hormone therapy link to neurocognitive decline

Both traditional hormone therapy and novel androgen receptor signaling inhibitors may be associated with neurocognitive impairment in men with prostate cancer, suggests WHO pharmacovigilance data.

13-04-2022 | Oncology | News | Article

Enhanced mortality risk reduction with adjuvant RT in men with LN-positive prostate cancer

All-cause mortality is significantly reduced in men with prostate cancer receiving adjuvant versus early salvage radiotherapy, particularly if they have four or more positive pelvic lymph nodes, research suggests.

11-04-2022 | Oncology | News | Article

Bone screening uncommon in men given ADT for prostate cancer

Fewer than one in 10 older men initiating androgen deprivation therapy for localized or regional prostate cancer receive dual-energy x-ray absorptiometry screening to assess bone mineral density, US study findings indicate.

06-04-2022 | Oncology | News | Article

​​​​​​​PSMA-targeted radioligand therapy approved for US mCRPC patients

More information about this FDA announcement here

18-03-2022 | Oncology | News | Article

Screening MRI unnecessary to prevent mCRPC spinal cord compression

Magnetic resonance imaging screening plus pre-emptive treatment does not significantly reduce clinical spinal cord compression rates in patients with castration-resistant prostate cancer and spinal metastasis, PROMPTS trial data show.

04-03-2022 | Oncology | News | Article

CADMUS suggests role for multiparametric ultrasound in diagnosing prostate cancer

The CADMUS investigators report a “slightly lower” rate of detection of clinically significant prostate cancers with multiparametric ultrasound than multiparametric MRI, but a higher rate of referrals for biopsy.

01-03-2022 | Oncology | News | Article

EMA supports use of relugolix for prostate cancer

Read more on this recommendation here

28-02-2022 | Oncology | News | Article

DCVAC/PCa use alongside chemotherapy shows no additional mCRPC survival benefit

The active autologous dendritic cell-based immunotherapy DCVAC/PCa is well tolerated when combined with docetaxel plus prednisone but does not improve survival in men with metastatic castration-resistant prostate cancer, phase 3 study data show.

19-02-2022 | Oncology | News | Article

PRESIDE shows clinical benefit of continuing enzalutamide post progression

Continuing enzalutamide treatment in combination with docetaxel reduces the risk for progression versus placebo plus docetaxel in men with metastatic castration-resistant prostate cancer that progressed during enzalutamide monotherapy, PRESIDE study data show.

18-02-2022 | Oncology | News | Article

Early mCRPC promise shown for novel CYP11A1 inhibitor

ODM-208, a novel nonsteroidal inhibitor of CYP11A1, has demonstrated promising antitumor activity in previously treated patients with metastatic castration-resistant prostate cancer enrolled in the first-in-human CYPIDES study.

18-02-2022 | Oncology | News | Article

​​​​​​​PROpel: mCRPC patients benefit from add-on olaparib

Supplementing first-line abiraterone acetate with olaparib significantly improves the outcomes of patients with metastatic castration-resistant prostate cancer, show phase 3 data reported at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA.

18-02-2022 | Oncology | News | Article

Adding niraparib to abiraterone boosts mutated mCRPC outcomes

Men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations could benefit from the addition of niraparib to first-line abiraterone acetate plus prednisone, suggest phase 3 trial data.

18-02-2022 | Oncology | News | Article

Darolutamide add-on prolongs survival in mHSPC

Adding the androgen receptor inhibitor darolutamide to androgen-deprivation therapy plus docetaxel significantly improves overall survival in men with metastatic hormone-sensitive prostate cancer, show data from the phase 3 ARASENS trial.

17-02-2022 | Oncology | News | Article

Health-related QoL data support olaparib use in HRR-mutated mCRPC

Olaparib use is associated with reduced pain burden and better preservation of health-related quality of life relative to control treatments in men with metastatic castration-resistant prostate cancer harboring BRCA1, BRCA2, or ATM alterations, research shows.